AstraZeneca vaccine newest
For much of the session, the Pound has come under notable stress and while a huge portion of this has been due to standing squaring, most especially in EUR/GBP, having corrected to the mid-0.86s. There’s also been increasing risks within the AstraZeneca vaccine and its link to rare forms of blood clots.
BLOOD CLOT LINK: The EMA stated that unusual blood clotting with Astrazeneca vaccine should be listed as a potential but rare side effect, however, reiterated the benefits continue to outweigh the side effects. The identical conclusion had been reached from the UK MHRA who additionally stated that the advantages are still quite favourable for the vast majority of people. That said the UK have noticed that those under 30 should be offered an alternate to the Astra vaccine, such as Pfizer or Moderna. Although, the UK Chair of Vaccine group have explained that they will not be advising a stop to some vaccination for any person in any age classes.
ROLLOUT TIMELINE: In regard to the vaccine rollout timeline, the UK’s Deputy Chief Medical Officer, Van Tam, says the effects of the on the overall schedule for the rollout of vaccines should be”zero or negligible”.
GBP REACTION: Since the beginning of the press conference the Pound has modestly recouped some losses as medical advisers continue to imply that the advantages outweigh the dangers, while the UK has said that the rollout program will not be adversely impacted. Keep in mind that the UK have several vaccines to void any gaps in the rollout of the Astra vaccine, such as the Pfizer vaccine as well as the recently rolled out Moderna vaccine.
